TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02658994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking Healthy Program Peer Delivered Plus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Study: NCT04103398

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE+sorafenib
Description: The initial dose of sorafenib is 400mg BID and the drug therapy will last till outcome events happen or the trial ends. TACE will start one day following oral sorafenib. Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Either conventional TACE (cTACE) or drug-eluting beads TACE (dTACE) is optional. TACE will be performed via injecting chemotherapy drugs (doxorubicin 50mg for cTACE or 75mg for dTACE) and embolizing agents (gelatin sponge for cTACE or microsphere for dTACE) into blood vessels that help tumor grow.
Study: NCT05084794

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal fixation
Description: Fixation of posterior malleolus with either plate or screws.
Study: NCT01573507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium lactate infusion
Description: 3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
Study: NCT01380444

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma3 Intramedullary Nails (Stryker)
Description: The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sliding Hip Screws
Description: The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
Study: NCT01689844

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DASH Plus
Description: DASH diet advice and guided shopping for high postassium foods at a local supermarket

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DASH - C
Description: Brief DASH dietary advice, No shopping guidance at the local supermarket.
Study: NCT03958136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasis biopsy
Description: Metastasis biopsy will be performed for multi-omic analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasis biopsy
Description: Metastasis biopsy will be performed for multi-omic analysis
Study: NCT02579239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion
Study: NCT03958136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metastasis biopsy
Description: Metastasis biopsy will be performed for multi-omic analysis
Study: NCT01709136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
Study: NCT00212303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Description: Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
Study: NCT04363437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: People in the colchine group will be given a starting dose of 1.2 mg followed, by 0.6mg after 2 hours if they do not have significant gastrointestinal symptoms, on day 1. After that, they will take colchicine 0.6mg twice a day for 14 days or until discharged or release from the hospital.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: COVID Patients in this arm will receive usual care COVID19 treatment and will not receive colchine.
Study: NCT01527227

Intervention type: OTHER
Intervention: questionnaires
Description: The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
Study: NCT00286130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX 6
Description: FOLFOX 6:~* Oxaliplatin 100 mg/m² d1 concurrent with~* Leucovorin 400 mg/m², followed by~* Bolus 5FU 400 mg/m² , followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: FOLFIRI:~* Irinotecan 180 mg/m² day 1 concurrent with~* Leucovorin 400 mg/m² followed by~* Bolus 5FU 400 mg/m², followed by~* Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
Study: NCT01079533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped CRCS Interventions
Description: In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
Study: NCT01605344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI.
Description: All patients will receive FOLFIRI infusion on day 1 and day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI.
Description: All patients will receive FOLFIRI infusion on day 1 and day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
Study: NCT02681055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-001
Description: MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
Study: NCT03270553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plazomicin
Description: single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plazomicin
Description: single intravenous dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: single oral dose
Study: NCT02326467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Bi-weekly chlorhexidine baths
Study: NCT00434512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV vaccine 732461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV vaccine 732461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV vaccine 732461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV vaccine 732461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV vaccine 732461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV vaccine 732461
Study: NCT03958136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biomarkers blood, urine and microbiota samples
Description: Biomarkers blood, urine and microbiota samples for multi-omic analysis
Study: NCT01373866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagPro X100 repetitive Transcranial Magnetic Stimulation
Description: Target defined using both fMRI during hallucinations occurence and tractography.~Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MagPro X100 repetitive Transcranial Magnetic Stimulation
Description: Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
Study: NCT02705508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: 2500U/m2 im on day 1 of each 21 day cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: involved-field radiotherapy
Description: Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
Study: NCT02494388

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided needle based confocal endomicroscopy
Description: Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided needle based confocal endomicroscopy
Description: Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided needle based confocal endomicroscopy
Description: Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided needle based confocal endomicroscopy
Description: Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.

Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound guided needle based confocal endomicroscopy
Description: Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
Study: NCT04061252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4827
Description: brodalumab 210mg Q2W, SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Q2W, SC
Study: NCT01136668

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block
Description: A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
Study: NCT01467648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: (i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: (ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.~Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem.
Study: NCT03968614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric dry needling and conventional PT
Description: Electrical Dry Needling, Eccentric Exercise, Stretching and Manual Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PT
Description: Eccentric Exercise, Stretching and Manual Therapy
Study: NCT02935699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Drug (JDP-205)
Description: Cetirizine, 10mg/mL; a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study: NCT02579239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATYR1940
Description: Concentrate for solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Concentrate for solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Concentrate for solution for infusion
Study: NCT02935699

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control (Diphenhydramine)
Description: Diphenhydramine Injection, 50 mg/mL;a single 1.0 mL injection via intravenous (IV) push over a period of \~2 minutes
Study: NCT00111917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: anti-TNF

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion
Study: NCT02066753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild therapeutic hypothermia
Description: Mild therapeutic hypothermia with a target temperature between 32-34°C.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia
Description: Mild therapeutic hypothermia with a target temperature between 32-34°C.
Study: NCT00012012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine trihydrate
Description: Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m\^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy
Description: For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy
Description: For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
Study: NCT02657915

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB033 100mg/Kg
Description: Administered as specified in the treatment arm.
Study: NCT01797744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
Study: NCT04676074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Upper limb( body) ergometer
Description: Electronic pedal for the upper limb using for training the upper body. Intensity, speed and resistance can be adjusted.
Study: NCT02022852

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
Study: NCT03446651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysine Chloride
Description: Patients will receive 7 days of therapy using 115 mmol/day of lysine chloride. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 7 days of therapy using placebo. Patients will be given the option of a taste test of both lysine chloride \& the placebo powders mixed with various beverages to ensure it is palatable to them. If the patient feels they will not be able to take the study medication twice a day due to taste, they will be withdrawn from the study at this time.
Study: NCT03958136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biomarkers blood, urine and microbiota samples
Description: Biomarkers blood, urine and microbiota samples for multi-omic analysis

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome (PRO)
Description: Patient Reported Outcome (PRO) will be collected throughout the study duration to assess quality of life, anxiety, depression distress, physical activity and food habits.